José Moltó

TL;DR: Mild and clinically tolerable neuropsychiatric disorders may persist in patients after a mean of 2 years using an efavirenz-based approach and Interventions to enhance long-term adherence should be applied in clinical practice.

TL;DR: The addition of ezetimibe to ongoing pravastatin seems to be an effective and safe option for HIV-infected patients not achieving the NCEP ATPIII LDL-cholesterol goals while receiving a statin alone.

TL;DR: Co-administration of ddI at standard doses plus TDF appears to exert a deleterious effect on CD4 and CD8 counts, although lymphocyte toxicity related to excessive ddI plasma levels could explain the findings, other mechanisms cannot be excluded.

TL;DR: CD4 T cell apoptosis by the intrinsic pathway represents the determinant mechanism of the unsatisfactory immune recovery and should be targeted to manage therapy for discordant patients, according to a cross-sectional, case-control study.

TL;DR: It is observed that both ddA-TP and TFV-DP have very long IC half-lives, resulting in unusual IC pharmacokinetic profiles with no significant changes in triphosphate concentrations between two dosings, which could have some drawbacks in terms of virus resistance for patients discontinuing these drugs.